Resistance Training on Growth Factors

January 30, 2024 updated by: Chongwen Zuo, Air Force Military Medical University, China

Acute Effect of Resistance Training With Different Intensity on Circulating Levels of Neurotrophic Growth Factors and Homocysteine in Young Adults

The goal of this clinial trial study is to explore the effect of high or low intensity resistance training (LIRT) under similar training volume on change in serum levels of BDNF, IGF-1, VEGF, irisin, and plasma Hcy in young adults.The main questions it aims to answer are:

  1. Whether high and low intensity will increase the serum levels of BDNF, IGF-1, VEGF, irisin, and reduce plasma Hcy.
  2. whether a greater magnitude of change would be suffer in low intensity group when compared to high intensity group, as an effect of greater physiological adaptation produced by more repetitions required to complete.

Participants will performe two different intensity resistance training (HIRT, at 80%1RM with 12 repetitions and 4-5 sets and LIRT, at 40%1RM with 24 repetitions and 4-5 sets).

Researchers will compare the training effects of two different training on these growth factors.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
12

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • age between 18 to 30 years
  • no experiencing musculoskeletal disorders or sports injuries
  • had not participated any regular aerobic endurance or resistance training with in the previous half years
  • no smoking habit or intake alcohol and other medication (e.g., steroid hormone)
  • good general body condition without any chronic diseases (e.g., osteoarthritis, metabolic syndrome or arthritis)

Exclusion Criteria:

  • experiencing musculoskeletal disorders or sports injuries in recent 1 month
  • had regular resistance training exercise
  • intake any supplementary(drug and hormone)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: High-intensity resistance training group (HIRT)
All subjects were instructed to conduct HIRT consisted of 4-5 sets of 12 repetitions at 80%1RM, with 1-2 minutes rests between each set.
Other: High intensity resistance training
The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
Experimental: low-intensity resistance training group (LIRT)
All subjects were instructed to conduct LIRT consisted of 4-5 sets of 24 repetitions at 40%1RM, with same period) in random order.
Other: Low intensity resistance training
For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Rata of perceived exertion
Time Frame: "0 minutes" "60 minutes" "90 minutes"
The rating of perceive exertion (RPE) questionnaire scale was applied to assess participants' subjective fatigue feeling throughout the training period.
"0 minutes" "60 minutes" "90 minutes"
Blood lactate
Time Frame: "0 minutes" "60 minutes" "90 minutes"
serum blood lactate
"0 minutes" "60 minutes" "90 minutes"
BDNF
Time Frame: "0 minutes" "60 minutes" "90 minutes"
regulators of neurogenesis
"0 minutes" "60 minutes" "90 minutes"
IGF-1
Time Frame: "0 minutes" "60 minutes" "90 minutes"
regulators of neurogenesis
"0 minutes" "60 minutes" "90 minutes"
VEGF
Time Frame: "0 minutes" "60 minutes" "90 minutes"
regulators of neurogenesis
"0 minutes" "60 minutes" "90 minutes"
Irisin
Time Frame: "0 minutes" "60 minutes" "90 minutes"
regulators of neurogenesis
"0 minutes" "60 minutes" "90 minutes"
Hcy
Time Frame: "0 minutes" "60 minutes" "90 minutes"
homocysteine (Hcy) increase with age and resulted in cognitive function decline through greater oxidative stress and vascular dysfunction
"0 minutes" "60 minutes" "90 minutes"

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Reactive time
Time Frame: "0 minutes" "60 minutes" "90 minutes"
Reaction time is the time it takes for the body to go from receiving a stimulus to responding to an action
"0 minutes" "60 minutes" "90 minutes"
Accuracy rate
Time Frame: "0 minutes" "60 minutes" "90 minutes"
Accuracy refers to the correct degree of expression or description of a thing, which is used to reflect the correct answer to the thing
"0 minutes" "60 minutes" "90 minutes"

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Air Force Military Medical University, China

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Chongwen Zuo, Doctoral, Air Force Medical Center of Chinese PLA

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 27, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 30, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 7, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 24, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 27, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 2, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 1, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 30, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • zuochongwen

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher. First author should be contacted if someone wants to request the data from this study.

IPD Sharing Time Frame

When this study was published.

IPD Sharing Access Criteria

Shall not be used for secondary analysis or repeated publication

IPD Sharing Supporting Information Type

  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings